Apellis Pharmaceuticals, Inc. reports news on its commercial-stage biopharmaceutical business centered on complement science and C3-targeting medicines. Recurring updates cover SYFOVRE, a pegcetacoplan injection for geographic atrophy secondary to age-related macular degeneration, and EMPAVELI, pegcetacoplan for rare diseases including paroxysmal nocturnal hemoglobinuria and rare kidney indications.
Company news also includes product revenue updates, ophthalmology and nephrology data presentations, pipeline references tied to complement biology, board and governance changes, investor conference participation, collaboration matters, and corporate-status developments involving strategic transactions and related shareholder communications.
S&P Dow Jones Indices will revise the S&P SmallCap 600 effective before market open on May 14, 2026. Bright Horizons (BFAM) and Remitly Global (RELY) will be added; Tri Pointe Homes (TPH) and Apellis Pharmaceuticals (APLS) will be removed.
Removals follow announced acquisitions of Tri Pointe by Sumitomo Forestry and Apellis by Biogen, each described as expected to close soon pending final closing conditions.
Summary not available.
Summary not available.
Biogen to acquire Apellis (Nasdaq: APLS) for $41.00 per share in cash, ~ $5.6 billion upfront plus a contingent value right (CVR) tied to SYFOVRE® sales.
The acquisition adds two commercial complement therapies (EMPAVELI® and SYFOVRE®; combined 2025 net sales $689 million), is expected to be accretive to non-GAAP EPS starting 2027, and to strengthen Biogen’s nephrology franchise ahead of a Phase 3 felzartamab readout in H1 2027.
Apellis (Nasdaq: APLS) announced that Mikael Dolsten, M.D., Ph.D., joined its board of directors effective March 1, 2026. Dr. Dolsten served more than 16 years as chief scientific officer and president, worldwide R&D and medical, at Pfizer and presided over regulatory approval of more than 36 medicines and vaccines.
He brings extensive pharma R&D leadership, previous roles at multiple major firms, current public and private board service, and advisor roles with investment groups to support Apellis’ complement-focused pipeline.
Apellis (Nasdaq: APLS) reported full-year 2025 net product revenues of $689 million—SYFOVRE $587 million and EMPAVELI $102 million. Cash and cash equivalents were $466.2 million at year-end. The company recorded a one-time $275 million upfront from Sobi and expects SYFOVRE prefilled syringe submission in H1 2026.
Apellis reported full-year net income of $22.4 million and faces a larger Q4 net loss of $58.9 million; EMPAVELI launches and pivotal kidney trials are underway.
Apellis (Nasdaq: APLS) will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.
The live webcast will be posted on the company’s Events and Presentations investor page and a replay will be available for approximately 30 days following the event.
Apellis (Nasdaq: APLS) will present eight oral abstracts at the 49th Macula Society Annual Meeting, Feb 25-28, 2026 in San Diego, including five-year results from the GALE extension (n=792) showing impact of early, continuous SYFOVRE (pegcetacoplan) treatment on geographic atrophy progression.
Presentations cover GALE, OAKS & DERBY analyses, AI imaging, real-world treatment patterns, and safety/visual function findings.
Apellis Pharmaceuticals (Nasdaq: APLS) will host a conference call and webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results.
Investors can preregister to access the live call by phone, view a live audio webcast and slides via the company’s Investors and Media Events and Presentations page, and access a replay for 30 days.
LegalZoom (NASD: LZ) will join the S&P SmallCap 600 effective prior to market open on Feb 2, 2026, as S&P Dow Jones Indices adjusts both the S&P MidCap 400 and S&P SmallCap 600.
Multiple additions and deletions occur on Jan 30, 2026 and Feb 2, 2026, including TTM Technologies, Dutch Bros, Advanced Energy Industries, American Healthcare REIT, and corresponding deletions tied to pending mergers and a liquidation.